TIGIT blockade
Antibodies against TIGIT, a brake on T cells and natural killer cells, tested alongside PD-L1 drugs; the biggest lung cancer trials so far have failed.
Overview
TIGIT is an inhibitory receptor on T and natural killer cells that competes with the activating receptor CD226 for the ligand CD155. Tiragolumab (Roche) reached phase 3 with atezolizumab after promising phase 2 results in lung cancer, but the SKYSCRAPER programme did not improve survival, and several rivals paused development. Fc-active and Fc-silent antibodies, and combinations in other tumours, are still being tested.
How it works
Monoclonal antibodies bind TIGIT to stop it engaging CD155, freeing CD226 co-stimulation; Fc-active versions may also deplete regulatory T cells.
- Complements PD-1/PD-L1 blockade mechanistically
- Well tolerated in trials
- Phase 3 lung cancer trials negative
- Benefit, if any, confined to undefined subgroups
- Fc-format questions unresolved
Latest papers
topQuery for this technology: (TITLE:"TIGIT blockade" OR ABSTRACT:"TIGIT blockade") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TIGIT blockade, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentHB0036
Shares TIGIT, Non-small-cell lung cancer.
- PairingCaution: TIGIT + PD-(L)1 blockade
Shares TIGIT, Tiragolumab, Non-small-cell lung cancer.
- TreatmentRilvegostomig
Shares TIGIT, Non-small-cell lung cancer.
- TargetTIM-3
Shares TIGIT, Non-small-cell lung cancer.
- PathwayT-cell exhaustion
Shares TIGIT, Tiragolumab.
- PathwayNK-cell recognition: missing self & stress ligands
Shares TIGIT, Tiragolumab.